Group 1 - The core point of the article highlights that BeiGene's stock closed at 51.42 yuan, with a slight increase of 0.76% on January 14 [1] - A significant block trade occurred, involving a total of 144,700 shares and a transaction amount of 5.9067 million yuan, with a transaction price of 40.82 yuan per share, reflecting a discount of 20.61% [1] - Over the past three months, the stock has seen a total of 9 block trades, accumulating a transaction amount of 43.6933 million yuan [1] Group 2 - In the last five trading days, the stock has increased by 3.71%, while the net outflow of main funds amounted to 45.7447 million yuan [1]

Core Viewpoint - The company is progressing with its Hong Kong listing application and is currently operating normally with stable cash flow [2] Group 1 - The company is actively responding to investor inquiries regarding its operations and listing status [2] - The application for the Hong Kong listing is being carried out in an orderly manner [2] - The company's current operational status is stable, indicating a healthy cash flow situation [2]

Core Viewpoint - The company emphasizes the importance of strategic partnerships and is actively seeking diverse collaboration opportunities with leading global biopharmaceutical firms, promising to disclose any significant developments in a timely manner [1] Group 1 - The company is focused on strategic cooperation and is engaging with top global biopharmaceutical companies [1] - The company is exploring various collaboration methods to enhance its strategic partnerships [1] - The company commits to timely announcements regarding any major progress in its partnerships [1]

Core Viewpoint - The company emphasizes its commitment to legal compliance and timely information disclosure in response to investor inquiries [1] Group 1 - The company stated that it adheres to laws, regulations, and exchange rules regarding information disclosure [1] - The establishment of wholly-owned subsidiaries is considered a routine business operation and does not fall under mandatory disclosure requirements [1]

Group 1 - The company, BeiGene, submitted an application for the issuance of overseas listed shares (H shares) and for listing on the Hong Kong Stock Exchange on September 29, 2025 [2] - The application materials for this issuance and listing were published on the Hong Kong Stock Exchange's website on the same day [2] - The related work for the Hong Kong stock listing is progressing in an orderly manner, and the company will announce any significant developments in a timely manner [2]

Group 1 - The core concern raised by investors is about the potential delay in the listing of MCLA-129, suggesting that if it is not submitted soon, the competitive landscape may diminish significantly [2] - Beida Pharmaceutical (300558.SZ) has responded that the clinical trial work for MCLA-129 is progressing in an orderly manner and that the company will announce any significant developments in a timely manner [2]

Group 1 - The company has scheduled the disclosure date for its 2025 annual report on April 23, 2026, which is later than many peers [2] - The company responded to investor concerns regarding the late reporting date, indicating that it is due to the progress of business operations [2] - The company assures that its operations are normal and advises stakeholders to refer to official disclosures for performance-related information [2]

Group 1 - The company is currently advancing the clinical trial work for MCLA-129 in an orderly manner [1] - The company will promptly announce any significant progress regarding MCLA-129 [1]

投资者提问： 您好！公司已按工作业务的相关进展预约2026年4月23日为2025年年度报告披露日。目前公司经营正 常，2025年业绩相关信息请以公司公开披露为准。谢谢！查看更多董秘问答>> 为什么年报时间这么晚，几乎就是最后几个，是不是业绩亏损？为什么不直接4.30日披露？ 董秘回答(贝达药业SZ300558)： 免责声明：本信息由新浪财经从公开信息中摘录，不构成任何投资建议；新浪财经不保证数据的准确 性，内容仅供参考。 ...

Core Viewpoint - The company has completed the equity transfer with Garden Group, acquiring a 20% stake in Hangzhou Zhixing Pharmaceutical, which specializes in high-end inhalation formulations [1] Group 1: Investment Details - The company invested 50 million yuan to acquire the 2 million yuan registered capital of Zhixing Pharmaceutical [1] - The post-investment ownership in Zhixing Pharmaceutical is 20% [1] Group 2: Company and Product Focus - Zhixing Pharmaceutical focuses on the development of high-end inhalation formulations, with a strong background in core technical personnel and a well-established R&D and production system [1] - Inhalation formulations are defined as drug delivery systems that utilize inhalation devices to administer medication to the respiratory tract, offering local or systemic therapeutic effects [1] Group 3: Market Potential and Applications - Inhalation formulations are recommended by domestic and international guidelines as the preferred treatment for asthma and chronic obstructive pulmonary disease (COPD) [1] - The technology is expanding into other fields, including vaccines and central nervous system applications, and offers new exploration directions for lung cancer treatment due to its targeted delivery and flexibility [1] - The company's investment aligns with its long-term strategic development in the high-end inhalation formulation sector, fostering deep collaboration in innovation and technology platforms [1]